Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Cancer Chemotherapy and Pharmacology
|
December 15, 2015
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
S Cereda, M Milella, S Cordio, et al.
British Journal of Cancer
|
September 24, 2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
E Van Cutsem, C-P Li, E Nowara, et al.
British Journal of Cancer
|
May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
M Reni, E Giommoni, F Bergamo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
Minerva Chirurgica
|
November 5, 1999
[The topical therapy of ulcerative colitis. A multicenter study with beclomethasone dipropionate foam]
R Arcidiacono, G Zanasi, Z Pirone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Cancer Chemotherapy and Pharmacology
|
December 15, 2015
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
S Cereda, M Milella, S Cordio, et al.
British Journal of Cancer
|
September 24, 2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
E Van Cutsem, C-P Li, E Nowara, et al.
British Journal of Cancer
|
May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
M Reni, E Giommoni, F Bergamo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
Minerva Chirurgica
|
November 5, 1999
[The topical therapy of ulcerative colitis. A multicenter study with beclomethasone dipropionate foam]
R Arcidiacono, G Zanasi, Z Pirone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
Page
of 6